长链非编码 RNA 对糖尿病肾病的影响：系统评价和计算分析。
The Impact of lncRNA on Diabetic Kidney Disease: Systematic Review and In Silico Analyses.
机构信息
College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Endocrinology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
出版信息
Comput Intell Neurosci. 2022 Apr 27;2022:8400106. doi: 10.1155/2022/8400106. eCollection 2022.
BACKGROUND
Long noncoding RNA (lncRNA) is involved in the occurrence and development of diabetic kidney disease (DKD). It is necessary to identify the expression of lncRNA from DKD patients through systematic reviews, and then carry out silico analyses to recognize the dysregulated lncRNA and their associated pathways.
METHODS
The study searched Pubmed, Embase, Cochrane Library, WanFang, VIP, CNKI, and CBM to find lncRNA studies on DKD published before March 1, 2021. Systematic review of the literature on this topic was conducted to determine the expression of lncRNA in DKD and non-DKD controls. For the dysregulated lncRNA in DKD patients, silico analysis was performed, and lncRNA2Target v2.0 and starBase were used to search for potential target genes of lncRNA. The Encyclopedia of Genomics (KEGG) pathway enrichment analysis was performed to better identify dysregulated lncRNAs in DKD and determine the associated signal pathways.
RESULTS
According to the inclusion and exclusion criteria, 28 publications meeting the eligibility criteria were included in the systematic evaluation. A total of 3,394 patients were enrolled in this study, including 1,238 patients in DKD group, and 1,223 diabetic patients, and 933 healthy adults in control group. Compared with the control, there were eight lncRNA disorders in DKD patients (MALAT1, GAS5, MIAT, CASC2, NEAT1, NR_033515, ARAP1-AS2, and ARAP1-AS1). In addition, five lncRNAs (MALAT1, GAS5, MIAT, CASC2, and NEAT1) participated in disease-related signal pathways, indicating their role in DKD. . This study showed that there were eight lncRNAs in DKD that were persistently dysregulated, especially five lncRNAs which were closely related to the disease. Although systematic review included 28 studies that analyzed the expression of lncRNA in DKD-related tissues, the potential of these dysregulated lncRNAs as biomarkers or therapeutic targets for DKD remains to be further explored. Trial registration. PROSPERO (CRD42021248634).
背景
长链非编码 RNA（lncRNA）参与了糖尿病肾病（DKD）的发生和发展。有必要通过系统评价从 DKD 患者中识别 lncRNA 的表达，然后进行计算机分析以识别失调的 lncRNA 及其相关途径。
方法
该研究检索了 Pubmed、Embase、Cochrane 图书馆、万方、VIP、CNKI 和 CBM，以查找 2021 年 3 月 1 日前发表的关于 DKD 的 lncRNA 研究。对该主题的文献进行了系统评价，以确定 DKD 和非 DKD 对照组中 lncRNA 的表达。对于 DKD 患者中失调的 lncRNA，进行了计算机分析，并使用 lncRNA2Target v2.0 和 starBase 搜索 lncRNA 的潜在靶基因。对基因组百科全书（KEGG）途径进行了富集分析，以更好地识别 DKD 中失调的 lncRNA 并确定相关信号途径。
结果
根据纳入和排除标准，有 28 篇符合入选标准的文献被纳入系统评价。共有 3394 名患者纳入本研究，其中 DKD 组 1238 例，糖尿病组 1223 例，对照组健康成人 933 例。与对照组相比，DKD 患者中有 8 种 lncRNA 紊乱（MALAT1、GAS5、MIAT、CASC2、NEAT1、NR_033515、ARAP1-AS2 和 ARAP1-AS1）。此外，有 5 种 lncRNA（MALAT1、GAS5、MIAT、CASC2 和 NEAT1）参与了疾病相关信号通路，表明其在 DKD 中的作用。本研究表明，DKD 中有 8 种 lncRNA 持续失调，尤其是与疾病密切相关的 5 种 lncRNA。尽管系统评价包括 28 项研究分析了 DKD 相关组织中 lncRNA 的表达，但这些失调 lncRNA 作为 DKD 生物标志物或治疗靶点的潜力仍有待进一步探索。试验注册。PROSPERO（CRD42021248634）。
Zotero 插件